Adding Serplulimab to Chemotherapy Improves Survival in Squamous NSCLC

Serplulimab plus chemotherapy is associated with longer survival than chemotherapy alone in first-line treatment of squamous NSCLC.

Related Keywords

China ,Shanghai ,Caicun Zhou , ,Shanghai Pulmonary Hospital ,